Ondine Biomedical Share Discussion Threads

[luzley] 19/3/2024 18:49

Good rise on strong volume

[z1co] 19/3/2024 15:31

The share price will rise above 20p on news regarding the start of pivotal US phase 3 trials.

[z1co] 19/3/2024 15:25

It's now 10.4p to BUY 50,000 , expect some more large trades to appear after the close.

[z1co] 19/3/2024 15:05

WOW , nearly 7m shares traded so far today.

Highest volume for more than a year.

[z1co] 19/3/2024 13:37

Largest buy for sometime , 250,000 at full of 10p

[z1co] 19/3/2024 11:48

108,529 shares bought at 10.35 reported an hour late increased the price by 0.125p.

[z1co] 19/3/2024 11:30

That 18,500 buy trade has now upped buying to 9.5858p for 50,000.

[z1co] 19/3/2024 11:23

Very strange from the MM's , you can BUY 50,000 shares at 9.50p but can SELL at 9.528p

[luzley] 19/3/2024 11:16

YHEC has direct input and influence into national NHS guidance.

[luzley] 19/3/2024 11:14

NHS trialsThis is the most recent news of interest since it has major implications for both NHS and Ondine5th March 24The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

[z1co] 18/3/2024 11:03

Unlike last year when they were announcing each hospital deal for Steriwave , they are
now beginning to deploy Steriwave at a much faster rate than 2023.In the announcement last week the company said that it has deployed Steriwave in six new hospitals to date in 2024.

In December 2023 the company said that it was in discussions with more than 75 hospitals regarding Steriwave in the UK , Mexico , Spain and Canada.

The Company also continues to work closely with HCA - the largest hospital group in the United States - to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine's submission to the FDA for approval

It looks like 2024 will be a massive year for the company.

[jailbird] 17/3/2024 21:30

Yes I agree but fund raises tends cause an overhang which holds the stock back longer Same goes for holders of cheap warrants

[bamboo2] 17/3/2024 10:46

jb, you could say the same about top slicing of any stock that has seen buyers at lower prices. In fact, it is necessary to have sellers, otherwise you never have any new holders.

[jailbird] 17/3/2024 08:09

Purple , You better learn about longer term investing because your 10% penny trade here has not happened .9p holders will top slice when it gets into the teens

[purple11] 16/3/2024 03:32

xXTiPSXHEETSXx


see CR Thread

[purple11] 15/3/2024 21:39

64 210 280 414

[z1co] 15/3/2024 15:52

Ondine Biomedical says progress has surpassed management expectations

Published: 07:39 15 Mar 2024 GMT


Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), a specialist in light-activated antimicrobial treatments, said its commercial progress so far this year has been ahead of management's expectations, buoyed by the deployment of its Steriwave technology in eight new healthcare facilities.

It brings the total number of hospitals using Steriwave to 22, nearly quadruple the number a year ago.

The Ottawa Hospital (TOH) is increasing its utilisation of Steriwave, extending its application from spinal to orthopaedic and vascular surgeries, anticipating its use in approximately 2,600 surgical procedures annually — a threefold increase from its pilot phase.

This decision follows a comprehensive cost-benefit analysis, highlighting Steriwave's effectiveness in reducing post-surgical infection rates and associated healthcare costs.

In addition to the domestic expansion, Ondine's international footprint is growing, with the first three hospitals in Spain, including Hospital Universitario La Paz (HULP) in Madrid, initiating a paid pilot on the Ondine technology.

This development is part of a strategy to address the rising global challenge of antibiotic resistance and the associated healthcare costs, as evidenced by recent findings showing a net saving of nearly C$2,600 per spine surgery patient treated with Steriwave and chlorhexidine skin decolonisation.

The expansion also includes the Sturgeon Community Hospital in Alberta, part of Canada's largest integrated health system, and the Nanaimo Regional General Hospital in British Columbia.

Both institutions have adopted Steriwave to reduce surgical site infections (SSIs) in various surgical procedures, further demonstrating the technology's applicability and efficacy across different medical specialties.

Ondine Biomedical is currently engaging with medical device distributors to broaden Steriwave's commercial reach.

[purple11] 15/3/2024 12:45

i really like the look of this one.gl

[purple11] 15/3/2024 12:22

22 62 114 430

[z1co] 15/3/2024 12:14

Any news from US regarding the pivotal phase 3 trials will send the shares way past 20p

[purple11] 15/3/2024 12:05

at some point the growth is going to go exponentially

these are when the big wins take place.
book your seat atb

[purple11] 15/3/2024 09:38

some nice 100k buys chewing up the stock

[z1co] 15/3/2024 08:46

The company has made significant commercial progress to date in 2024, ahead of management's expectations. Ondine's Steriwave® technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago.